develops and conducts studies, including economic and behavioral studies, to evaluate the effectiveness of interventions and programs to prevent viral hepatitis and to identify barriers to prevention services such as immunization, counseling, testing, medical referral, and management; (6) develops and evaluates health services models for prevention of infection with hepatitis viruses and associated liver disease; (7) provides leadership and coordinates the development of national standards and performance objectives for prevention of viral hepatitis and liver disease and works with agencies and partners to adopt these standards; (8) develops indicators and measures by which to evaluate the performance and effectiveness of viral hepatitis prevention programs; (9) disseminates information through scientific publications and presentations; and (10) provides training opportunities for Epidemic Intelligence Service Officers and others in CDC sponsored programs, postgraduate students, post-doctoral fellows, and other public health scientists.

Laboratory Branch (HCR44). (1) Conducts research and applies state-of-the-art laboratory methods in support of studies related to the epidemiology, molecular epidemiology, and natural history of acute and chronic infections with hepatitis viruses and liver disease; (2) conducts research to develop and validate diagnostic approaches to identify infections with hepatitis viruses; (3) develops and evaluates methods to prevent acute and chronic infection and disease outcomes, including vaccines; (4) determines the viral, immunologic, and other host responses to infection with hepatitis viruses in humans and animal models; (5) identifies and characterizes agents that cause hepatitis; (6) provides reference diagnostic testing for markers of infection with hepatitis viruses for state and local public health laboratories; (7) provides the leadership and collaboration to ensure the transfer to public health laboratories, both nationally and internationally, state-of-the-art methods and approaches for the identification and diagnosis of infections with hepatitis viruses; (8) develops and maintains archives of clinical specimens from clinical trials and epidemiologic and laboratory studies; (9) disseminates information through scientific publications and presentations; and (10) provides training opportunities for persons in CDC sponsored programs, postgraduate students, post-doctoral fellows, and other public health scientists.

Dated: April 14, 2002.

David W. Fleming,

Acting Director, CDC.

[FR Doc. 02–9248 Filed 4–16–02; 8:45 am]

BILLING CODE 4160–18–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 01E–0363]

Determination of Regulatory Review Period for Purposes of Patent Extension; MIFEPREX; Extension of Comment Period

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; extension of comment period.

SUMMARY: The Food and Drug Administration (FDA) is extending to April 26, 2002, the comment period for the regulatory review period determination for MIFEPREX, published in the **Federal Register** of January 25, 2002 (67 FR 3724). The agency is taking this action in response to a request for an extension.

DATES: Submit written or electronic comments on the regulatory review period determination for MIFEPREX by April 26, 2002.

ADDRESSES: Submit written comments and petitions to the Dockets Management Branch (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to http://www.fda.gov/dockets/ecomments.

FOR FURTHER INFORMATION CONTACT: Claudia V. Grillo, Office of Regulatory Policy (HFD–007), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–594–2041.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of January 25, 2002 (67 FR 3724), FDA published a document entitled ''Determination of Regulatory Review Period for Purposes of Patent Extension; MIFEPREX.'' The document set forth the determination of the regulatory review period for purposes of patent term extension for the human drug product MIFEPREX. The document announced that FDA determined that the applicable regulatory review period for MIFEPREX was 2,249 days, and that of this time, 593 days had occurred during the testing phase of the regulatory review period, while 1,656 days had occurred during the approval phase. The notice explained how these periods of time were derived.

FDA received a letter dated March 22, 2002, from an attorney representing the Population Council (the patent holder) and others, requesting that the agency extend the comment period on the regulatory review period for 30 days, until April 26, 2002, explaining that additional time was needed to reach a licensing agreement. FDA has determined that it is appropriate to grant this request.

Interested persons may submit to the Dockets Management Branch (see **ADDRESSES**) written or electronic comments on the regulatory review period determination for MIFEPREX on or before April 26, 2002. Three copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Comments and petitions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

Dated: March 27, 2002.

Jane A. Axelrad,

Associate Director for Policy, Center for Drug Evaluation and Research.

[FR Doc. 02–9364 Filed 4–16–02; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR–4734–N–14]

Notice of Submission of Proposed Information Collection to OMB; Small Cities Program Performance Assessment Report

AGENCY: Office of the Chief Information Officer, HUD.

ACTION: Notice.

SUMMARY: The proposed information collection requirement described below has been submitted to the Office of Management and Budget (OMB) for review, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal.

DATES: *Comments Due Date:* May 17, 2002.

ADDRESSES: Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name and/or OMB approval number (2506–0020) and should be sent to: Joseph F. Lackey, Jr., OMB Desk Officer, Office of Management and Budget, Room 10235, New Executive Office Building, Washington, DC 20503; Fax number